| PRECLINICAL | evidence | Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. | Semaglutide | — | 2026-06-16 |
| PRECLINICAL | evidence | MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | Obesity versus China: how Ozempic is complicating the world's largest weight loss campaign. | Ozempic | — | 2026-06-15 |
| PRECLINICAL | evidence | Can semaglutide influence tumor biomarkers? Insight from a clinical case. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Safety, Sarcopenic Morphologies, and Adapted Body Contouring Strategies. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-06-15 |
| PRECLINICAL | evidence | Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations. | Ozempic | — | 2026-06-15 |
| PRECLINICAL | evidence | Challenges in assessing statin-associated adverse events - Authors' reply. | Semaglutide | — | 2026-06-13 |
| PRECLINICAL | evidence | Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series. | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Boerhaave's syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report. | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Wegovy weight loss pill gets UK approval. | Wegovy | — | 2026-06-12 |
| PRECLINICAL | evidence | Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation. | Semaglutide | Liver health | 2026-06-12 |
| PRECLINICAL | evidence | Improvement of Refractory Restless Legs Syndrome in a Parkinson's Disease Patient After Semaglutide Treatment: A Novel Clinical Observation. | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Late-stage generation of (14)C/(3)H-radiolabeled lysine residues via hydroformylation of peptides. | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study. | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Re: Liu et al.: Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis (Ophthalmology 2026;133;589-598). | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. | Semaglutide | — | 2026-06-12 |
| PRECLINICAL | evidence | Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis. | Semaglutide | — | 2026-06-11 |
| PRECLINICAL | evidence | Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity. | Semaglutide | — | 2026-06-11 |
| PRECLINICAL | evidence | SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. | Semaglutide | Liver health | 2026-06-10 |
| PRECLINICAL | evidence | Functional Performance of Silk Nanoparticles for Oral Drug Delivery. | Semaglutide | — | 2026-06-10 |
| PRECLINICAL | evidence | Orofacial adverse events associated with Glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study. | Ozempic | — | 2026-06-09 |
| PRECLINICAL | evidence | Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review. | Semaglutide | — | 2026-06-09 |
| PRECLINICAL | evidence | Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials. | Ozempic | — | 2026-06-09 |
| PRECLINICAL | evidence | Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters. | Semaglutide | — | 2026-06-09 |
| PRECLINICAL | evidence | Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland. | Semaglutide | — | 2026-06-09 |
| PRECLINICAL | evidence | Exploratory associations between co-occurring opioid and alcohol use disorders and GIP/GLP-1 receptor agonist treatment. | Ozempic | — | 2026-06-09 |
| PRECLINICAL | evidence | Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Cohort Study. | Semaglutide | — | 2026-06-08 |
| PRECLINICAL | evidence | Early Generic Semaglutide in Canada-Implications for US Patients and Policy. | Semaglutide | — | 2026-06-08 |
| PRECLINICAL | evidence | Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations. | Semaglutide | — | 2026-06-08 |
| PRECLINICAL | evidence | Preventing GLP-1-Associated Facial Aging: An Anatomy-Driven Risk Stratification Model and Prevention Algorithm in the "Ozempic Face" Era. | Ozempic | — | 2026-06-08 |
| PRECLINICAL | evidence | Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study. | Semaglutide | — | 2026-06-07 |
| PRECLINICAL | evidence | Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025. | Semaglutide | — | 2026-06-07 |
| PRECLINICAL | evidence | GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. | Semaglutide | — | 2026-06-07 |
| PRECLINICAL | evidence | Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain. | Semaglutide | — | 2026-06-06 |
| PRECLINICAL | evidence | Weight loss associated with semaglutide use is linked to improved reproductive measures in polyendocrine metabolic ovarian syndrome: a proof-of-concept analysis. | Semaglutide | — | 2026-06-06 |
| PRECLINICAL | evidence | Clinical Effectiveness and Safety of Oral Semaglutide in a Real-World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score-Matched Analysis. | Semaglutide | — | 2026-06-05 |
| PRECLINICAL | evidence | Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome. | Semaglutide | — | 2026-06-05 |
| PRECLINICAL | evidence | Cross-sectional analysis of the reliability and engagement metrics of YouTube videos on semaglutide for weight loss. | Semaglutide | Weight & fat loss | 2026-06-05 |
| PRECLINICAL | evidence | Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study. | Semaglutide | — | 2026-06-04 |
| PRECLINICAL | evidence | Diabetic Status, Advanced Age, and Hispanic Ethnicity Predict Poorer Weight Loss in Patients With Obesity Receiving Semaglutide. | Semaglutide | — | 2026-06-04 |
| PRECLINICAL | evidence | Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents. | Semaglutide | — | 2026-06-03 |
| PRECLINICAL | evidence | Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus. | Semaglutide | Glycemic control | 2026-06-02 |
| PRECLINICAL | evidence | [Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults]. | Semaglutide | Glycemic control | 2026-06-02 |
| PRECLINICAL | evidence | Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System. | Semaglutide | — | 2026-06-02 |
| PRECLINICAL | evidence | Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats. | Semaglutide | — | 2026-06-02 |
| PRECLINICAL | evidence | Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study. | Semaglutide | — | 2026-06-02 |